・Analysts at BofA nearly doubled their price target for HIMS stock following the company’s deal with Novo. ・The firm now has a price target of $23, up from $12.5, while the rating has been upgraded to ...
The ad, which aired during the Super Bowl over the weekend, promoted a new product by Hims & Hers, a blood test designed to detect over 50 types of cancer before symptoms appear. This includes hard-to ...
Shares of Hims & Hers Health rose more than 7% on Thursday as analysts said the U. drug regulator's consideration to allow ...
Shares of Hims & Hers fell after hours on Monday after the wellness platform’s first-quarter profit forecast missed expectations, pressured by the money it spent on a Super Bowl ad and planned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results